Aptinyx
Biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 86.7x EV/Revenue -9.6x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $5.6m | Grant | |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (39 %) | (57 %) | (36 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (900 %) | (1625 %) | (3246 %) | (7453 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (883 %) | (1565 %) | (3200 %) | (7489 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 678 % | 1208 % | 2099 % | 5544 % | - |
Source: Company filings or news article
Related Content
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing transformative therapies for challenging disorders of the brain and nervous system. The company leverages its proprietary NMDA receptor modulator discovery platform to create novel therapeutic solutions for a range of central nervous system (CNS) disorders. Aptinyx's current pipeline includes multiple candidates in late-stage clinical development targeting conditions such as chronic pain and post-traumatic stress disorder (PTSD).
Aptinyx operates in the biopharmaceutical market, primarily serving patients suffering from CNS disorders. The business model is centered around the research and development of new drug candidates, which are then brought through clinical trials to demonstrate efficacy and safety. Revenue is generated through partnerships, licensing agreements, and eventually, the commercialization of successful therapies.
Keywords: biopharmaceutical, CNS disorders, NMDA receptor, chronic pain, PTSD, clinical-stage, drug development, therapeutic solutions, proprietary platform, late-stage clinical trials.